Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jennifer Haig, Martin Barbeau & Alberto Ferreira. (2016) Cost-effectiveness of ranibizumab in the treatment of visual impairment due to diabetic macular edema. Journal of Medical Economics 19:7, pages 663-671.
Read now
Read now
Samuel Robert Nyman, Bridget Dibb, Christina Rita Victor & Margot Ann Gosney. (2012) Emotional well-being and adjustment to vision loss in later life: a meta-synthesis of qualitative studies. Disability and Rehabilitation 34:12, pages 971-981.
Read now
Read now
Jordana K. Schmier, David W. Covert, G. Philip Matthews & Z. Nicholas Zakov. (2009) Impact of visual impairment on service and device use by individuals with diabetic retinopathy. Disability and Rehabilitation 31:8, pages 659-665.
Read now
Read now
Articles from other publishers (10)
Martijn S. Visser, Reinier Timman, Joanneke Kampen-Smalbrugge, Karin Buis, Jan Roelof Polling & J. J. V. Busschbach. (2020) Randomized Controlled Trial of a Spectacle Lens for Macular Degeneration. Optometry and Vision Science 97:10, pages 889-897.
Crossref
Crossref
Andrew A. Moshfeghi, Tereza Lanitis, Georg Kropat, Andreas Kuznik, Andrea Gibson, Haidong Feng & Jonathan Prenner. (2020) Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020. Ophthalmic Surgery, Lasers and Imaging Retina 51:S1.
Crossref
Crossref
Diane M. Gibson. (2018) Use of and disparities in access to adaptive devices among U.S. adults with age-related eye diseases. Preventive Medicine Reports 12, pages 233-240.
Crossref
Crossref
Annetta Smith, Ashley Shepherd, Ruth Jepson & Seonaid Mackay. (2015) The impact of a support centre for people with sensory impairment living in rural Scotland. Primary Health Care Research & Development 17:02, pages 138-148.
Crossref
Crossref
Murray H. Brilliant, Kamyar Vaziri, Thomas B. ConnorJr.Jr., Stephen G. Schwartz, Joseph J. Carroll, Catherine A. McCarty, Steven J. Schrodi, Scott J. Hebbring, Krishna S. Kishor, Harry W. FlynnJr.Jr., Andrew A. Moshfeghi, Darius M. Moshfeghi, M. Elizabeth Fini & Brian S. McKay. (2016) Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. The American Journal of Medicine 129:3, pages 292-298.
Crossref
Crossref
Jordana K. Schmier & Carolyn K. Hulme-Lowe. (2015) Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges. PharmacoEconomics 34:3, pages 259-272.
Crossref
Crossref
Jonathan L. Prenner, Lawrence S. Halperin, Catherine Rycroft, Susan Hogue, Zinaria Williams Liu & Robert Seibert. (2015) Disease Burden in the Treatment of Age-Related Macular Degeneration: Findings From a Time-and-Motion Study. American Journal of Ophthalmology 160:4, pages 725-731.e1.
Crossref
Crossref
Jordana K. Schmier, David W. Covert & Edmund C. Lau. (2012) Patterns and Costs Associated With Progression of Age-Related Macular Degeneration. American Journal of Ophthalmology 154:4, pages 675-681.e1.
Crossref
Crossref
Kathleen Melissa Ke. (2009) The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration. The European Journal of Health Economics 11:6, pages 525-531.
Crossref
Crossref
Omesh P Gupta, Gary C Brown & Melissa M Brown. (2007) Age-related macular degeneration: the costs to society and the patient. Current Opinion in Ophthalmology 18:3, pages 201-205.
Crossref
Crossref